Telara Pharma is proud to announce that it has been officially recognized with the Emerging Company Certification, granted by the Ministry of Industry and Tourism through ENISA (Empresa Nacional de Innovación SME, S.A.). This recognition is part of the broader framework of the “Startup Law”—formally known as the Law for the Promotion of the Emerging Companies Ecosystem. This forward-thinking legislation introduces a suite of measures designed to support the creation, development, and investment in high-potential startups.
Pioneering the Future
Receiving the Emerging Company Certification is a powerful validation of Telara Pharma’s innovative approach. This achievement marks a pivotal moment in Telara Pharma’s journey. With the backing of ENISA and the strategic benefits offered by the Startup Law, the company is well-positioned to accelerate its innovation pipeline and expand its reach.
The certification further solidifies Telara Pharma’s reputation as a forward-looking biotech enterprise, ready to make a meaningful difference in the healthcare sector.
About Telara Pharma
Telara Pharma is a clinical-stage biotechnology company focused on developing neuroprotective therapies for glaucoma and other neuroinflammatory diseases. Founded on over a decade of research into kidney protection and inflammation, the company is repurposing Cilastatin (CIL)—a well-characterized, FDA-approved molecule—for topical use in ophthalmology.
Telara’s lead program, CIL eye drops, offers a novel approach to glaucoma treatment by directly protecting retinal ganglion cells (RGCs), addressing the unmet need for therapies that go beyond intraocular pressure (IOP) reduction. Preclinical studies have shown that CIL prevents RGC damage and reduces retinal inflammation without altering IOP, positioning it as a first-in-class, add-on therapy.
Led by a seasoned management team with deep expertise in ophthalmology, pharmaceutical development, and translational science, Telara Pharma is committed to transforming proven science into impactful therapies that improve patients’ lives.